UNSPSC 51263311: Quinazosin

This classification denotes an alpha-adrenergic blocking agent with the molecular formula C17H23N5O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 436XK6QFMR, chemically known as 4-quinazolinamine, 6,7-dimethoxy-2-(4-(2-propenyl)-1-piperazinyl)- but generally known as quinazosin, which bears US NIH Compound Identifier 27486. European Medicines Agency schedules Quinazosin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB10203MIG.

UNSPSC 51263311 Quinazosin, a Commodity code, appears in state and local procurement with minimal recent activity; the single recorded opportunity shows a significant mismatch between the code's nominal pharmaceutical scope and actual purchasing need. Seminole County, Florida issued IFB 60459723LAS in June 2026 seeking procurement of naloxone (an opioid antagonist used in overdose reversal) and safe drug deactivation systems — neither of which aligns with quinazosin, an alpha-adrenergic antagonist used in hypertension management. The county requested 1,900 units of naloxone and 800 deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida, on a fixed-fee basis with an initial two-year term and one-year renewal option. The solicitation required electronic submission through the county's e-Procurement Portal, drug-free workplace certification, E-Verify compliance, and proof of workers' compensation, commercial general liability, and professional liability insurance. The contract potentially carried FEMA funding with associated federal compliance obligations.

The code shows no measurable recent activity under its stated pharmaceutical category across state and local jurisdictions. The single Seminole County opportunity represents a tagging error rather than authentic demand for quinazosin; procurement professionals should not treat this code as an active market for state and local contract pursuit. Geographic and issuing-body signals cannot be drawn from a single mistagged solicitation. Vendors currently pursuing state and local pharmaceutical procurements should monitor alternative UNSPSC classifications aligned with the actual active-pharmaceutical-ingredient categories state and local health departments, counties, and school districts are buying.